查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球肺癌藥物市場：按疾病類型、治療方法、藥物類別、給藥途徑、分銷管道和地區劃分的評估、機會和預測（2016-2030）
市場調查報告書
商品編碼
1388955

全球肺癌藥物市場：按疾病類型、治療方法、藥物類別、給藥途徑、分銷管道和地區劃分的評估、機會和預測（2016-2030）

Lung Cancer Therapeutics Market Assessment, By Disease Type, By Treatment, By Drugs Class, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2016-2030F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 204 Pages | 商品交期: 3-5個工作天內

價格

2022年全球肺癌治療市場規模為212億美元，2023-2030年預測期間複合年增長率為12.9%，預計到2030年將達到560億美元。 已開發國家和發展中國家對肺癌的認識不斷提高，推動了肺癌藥物的進步。 這種快速增長是由新的診斷工具、尖端治療的進步以及政府對改善衛生基礎設施和治療的關注所推動的。 提高大眾對多種肺癌治療方案的認識也是推動市場成長的關鍵因素。

此外，可支配收入的增加、創新技術研發的進展、尖端放射治療的引進、個人化醫療的日益重視以及新興國家和欠發達地區的經濟成長等因素，預計將推動整個預測期內市場的成長軌跡。 治療方案的進步大大改變了肺癌藥物的模式。 該市場正在經歷臨床試驗和研究的激增，探索新的治療方法、聯合療法和早期診斷方法，以改善患者的治療結果和存活率。 隨著全球醫療保健產業繼續優先考慮腫瘤學和個人化醫療，肺癌藥物市場有望進一步發展，推動確診患者生存率的提高、治療效果的提高以及生活品質的改善，這是令人期待的。

本報告分析了全球肺癌治療藥物市場，提供了產品概述、市場基本結構、整體市場規模趨勢展望、按細分市場和地區劃分的詳細趨勢以及背景情況我們調查了主要影響因素、主要公司概況和市場份額等。

目錄

第一章研究方法

第 2 章專案範圍與定義

第三章新型冠狀病毒感染（COVID-19）對全球肺癌治療藥物市場的影響

第 4 章執行摘要

第五章全球肺癌治療藥物市場未來展望（2016-2030）

  • 市場規模與預測
    • 基於金額
    • 基於數量
  • 依疾病類型
    • 非小細胞肺癌 (NSCLC)
    • 小細胞肺癌 (SCLC)
  • 依治療方法
    • 化療
    • 放射治療
    • 免疫治療/標靶治療
    • 其他
  • 依藥物類別
    • 免疫抑制劑
    • 單株抗體
    • 酪胺酸激□
    • 表皮生長因子受體 (EGFR)
    • 拓樸異構□抑制劑
    • 其他
  • 依給藥途徑
    • 口腔醫學
    • 注射藥品
  • 按分銷管道
    • 醫院
    • 專科診所
    • CRO（藥物開發合約組織）
    • 家庭醫療護理
    • 門診手術中心
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 各公司的市佔率（%，2022 年）

第六章全球肺癌治療市場的未來展望：按地區（2016-2030）

  • 北美*
    • 市場規模與預測
      • 基於金額
      • 基於數量
    • 依疾病類型
    • 依治療方法
    • 依藥物類別
    • 依給藥途徑
    • 按分銷管道
    • 美國*
      • 市場規模與預測
      • 依疾病類型
      • 依治療方法
      • 依藥物類別
      • 依給藥途徑
      • 按分銷管道
    • 加拿大
    • 墨西哥

為涵蓋的所有地區/國家提供每個細分市場的資訊。

  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 南美洲
    • 巴西
    • 阿根廷
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印尼
    • 菲律賓
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第 7 章市場地圖（2022 年）

  • 依疾病類型
  • 依治療方法
  • 依藥物類別
  • 依給藥途徑
  • 按分銷管道
  • 按地區

第八章宏觀環境與產業結構

  • 需求與供給分析
  • 進出口分析（數量/價值基礎）
  • 供應/價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 9 章市場動態

  • 生長促進因素
  • 抑製成長的因素（問題、限制）

第 10 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第十一章主要公司狀況

  • 前 5 名市場領導者：競爭矩陣
  • 前 5 位市場領導者：市場收入分析（%，2022 年）
  • 併購 (M&A)/合資企業（如果適用）
  • SWOT 分析（針對 5 家進入市場的公司）
  • 專利分析（如果適用）

第十二章價格分析

第 13 章案例研究

第14章主要公司展望

  • Novartis AG
    • 公司概況
    • 管理人員
    • 產品/服務
    • 財務狀況（據報告）
    • 重點市場與地域分佈
    • 近期趨勢
  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Hoffmann-La Roche
  • Merck &Co.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Abbvie (Allergan)
  • Johnson &Johnson (Janssen Pharmaceuticals)
  • Amgen Inc.

上面列出的公司並非按市場份額排序，並且可能會根據研究工作中獲得的資訊進行更改。

第十五章策略建議

第 16 章關於 Market Xcel，免責聲明

Product Code: MX10661

Global lung cancer therapeutics market size was valued at USD 21.2 billion in 2022 and is expected to reach USD 56 billion in 2030, with a CAGR of 12.9% for the forecast period between 2023 and 2030F. Advancements in lung cancer therapeutics have risen due to heightened awareness of the disease in both developed and developing nations. The surge is attributed to the evolution of new medical diagnostic tools and state-of-the-art therapies and governments' amplified focus on healthcare infrastructure and improved treatment provisions. Another crucial catalyst propelling market growth is the increasing public awareness about diverse lung cancer treatment options.

Furthermore, factors such as growing disposable incomes, ongoing research and development for innovative technologies, the introduction of cutting-edge radiation therapy, the growing emphasis on personalized medicine, and the expanding economies in developing and underdeveloped regions are expected to bolster the market's growth trajectory throughout the projected period. Advancements in treatment options have significantly transformed the landscape of lung cancer therapeutics. The market has seen a surge in clinical trials and research exploring novel therapies, combination treatments, and early diagnosis methods, all aimed at improving patient outcomes and survival rates. As the global healthcare industry continues to prioritize oncology and personalized medicine, the lung cancer therapeutics market is expected to witness further advancements, driving improved survival rates, enhanced treatment efficacy, and better quality of life for patients diagnosed.

Rising prevalence of lung cancer

The global lung cancer therapeutics market has experienced a concerning upsurge in the prevalence of lung cancer cases. Lung cancer remains a significant health challenge, contributing to a substantial portion of cancer-related mortality worldwide. Factors such as widespread smoking, environmental pollutants, and lifestyle changes contribute to the escalating incidence of lung cancer. As projected by the American Cancer Society, in 2022, there were about 236,740 estimated new cancer cases and 130,180 estimated deaths in the United States.

Advancements in medical technology and increased awareness have led to earlier detection, improving survival rates. However, the rise in cases continues to propel the demand for more effective therapeutic interventions. Pharmaceutical companies, medical researchers, and healthcare providers are intensively focusing on developing innovative treatments, including targeted therapies, immunotherapies, and personalized medicine, to address this growing concern.

Advancement in Therapies

The global lung cancer therapeutics market has witnessed significant advancements in recent years, marked by innovative approaches and therapies. Immunotherapy, particularly immune checkpoint inhibitors such as Pembrolizumab and Nivolumab, have revolutionized lung cancer treatment by improving the body's immune response against cancer cells. Targeted therapies like EGFR inhibitors (such as Erlotinib and Osimertinib) and ALK inhibitors (such as Alectinib and Crizotinib) have shown remarkable efficacy in specific genetic mutations, leading to more personalized and effective treatment options. Moreover, advancements in precision medicine and the utilization of liquid biopsies for early detection of genetic mutations have improved diagnosis and treatment decision-making. Emerging technologies like CAR-T cell therapy and novel drug delivery systems offer promising avenues for the future. These developments reflect a paradigm shift towards more tailored, effective, and less invasive therapies, enhancing the prognosis and quality of life for lung cancer patients.

In July 2023, Iovance Biotherapeutics completed an initial evaluation of the Phase II trial for its autologous tumor-infiltrating lymphocyte (TIL) therapy, Lifileucel (LN-145), in patients diagnosed with metastatic non-small cell lung cancer (NSCLC). A review by the US FDA suggested that the trial design might be appropriate for accelerated approval. The encouraging feedback from regulators is grounded in the utilization of Lifileucel among patients with advanced, non-genomic mutant NSCLC who have undergone at least one FDA-approved targeted treatment.

Strategic Initiatives by Key Players

Key players in the global lung cancer therapeutics market have been actively involved in strategic initiatives to advance treatment options and improve patient outcomes. Many companies have focused on research and development, investing heavily in innovative therapies and technologies. Initiatives include the development of targeted therapies, immunotherapies, and precision medicine approaches tailored to specific genetic mutations and biomarkers.

Key pharmaceutical companies have introduced novel therapies targeting specific mutations and mechanisms involved in lung cancer progression. For example, the development and release of immunotherapies such as PD-1/PD-L1 inhibitors have marked a substantial breakthrough, offering improved treatment efficacy and reduced side effects compared to traditional chemotherapy. For instance, during June 2022, the European Commission granted approval to Novartis for Tabrecta in treating advanced non-small cell lung cancer with METex14 skipping.

Increasing Progress in Research and Development

The global lung cancer therapeutic market is experiencing significant growth, largely driven by the rising demand for precision medicine, a foundation of which is targeted therapies. The increase in demand can be attributed to the increasing research and development efforts in the field. For instance, in July 2023, the publication of a ten-year clinical trial revealed that lung cancer patients with the epidermal growth factor receptor (EGFR) mutation experienced notably increased survival rates when administered the drug Osimertinib. This development marks a significant stride in the realm of precision medicine and opens new opportunities for clinical laboratories to provide added value to both physicians and patients. The ADAURA project, led by scientists at Yale University and supported by AstraZeneca, a British pharmaceutical and biotechnology company, spearheaded this research. When pathology tests identify the EGFR mutation in a patient, there's substantial evidence indicating that the use of this targeted therapy could potentially decrease lung cancer-related fatalities by up to 50%.

Impact of COVID-19

Patients diagnosed with lung cancer faced an increased vulnerability to COVID-19 infection due to their common intake of immunosuppressive and chemotherapeutic medications during treatment. Managing these patients amid the pandemic posed a persistent challenge. To address this difficulty, multiple organizations collaborated to propose solutions and guidelines. For instance, as documented, in a January 2022 article in the Journal for Immunotherapy of Cancer, the European Society for Radiotherapy and Oncology and the American Society for Radiation Oncology joined forces to recommend treatments for various stages of lung cancer, including non-small cell lung cancer (NSCLC) in stages I-III, prophylactic cranial irradiation for small cell lung cancer (SCLC), and palliative radiation for NSCLC.

Furthermore, these recommendations catered to both an 'early pandemic scenario', where balancing patient and radiotherapy staff safety with lung cancer treatment was crucial, and a 'later pandemic scenario', which involved limited resources and necessitated patient prioritization. Consequently, the collective efforts of these organizations to confront treatment challenges amplified the demand for lung cancer therapeutics. Moreover, due to lockdown measures, better access to treatments is now available compared to the initial phase of the pandemic, resulting in the market reaching pre-pandemic growth levels and anticipated substantial growth in the forecast period.

Key Players Landscape and Outlook

Key industry leaders are heavily investing in research and development to expand their product portfolios, fostering further growth within the lung cancer therapeutics sector. These players are pursuing diverse strategic actions to broaden their global presence, such as introducing new products, entering contracts, engaging in mergers and acquisitions, amplifying investments, advancing market strategies, and establishing collaborations with other organizations. Competitors in the market must provide cost-effective solutions to expand and endure in a progressively competitive and burgeoning market landscape.

In April 2022, the United States FDA accepted the supplemental Biologics License Application for Enhertu (trastuzumab deruxtecan) for treating unresectable or metastatic non-small cell lung cancer (NSCLC) in adult patients, developed by AstraZeneca and Daiichi Sankyo.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on the Global Lung Cancer Therapeutics Market

4. Executive Summary

5. Global Lung Cancer Therapeutics Market Outlook, 2016-2030F

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. By Disease Type
    • 5.2.1. Non-small Cell Lung Cancer (NSCLC)
    • 5.2.2. Small Cell Lung Cancer (SCLC)
  • 5.3. By Treatment
    • 5.3.1. Chemotherapy
    • 5.3.2. Radiation Therapy
    • 5.3.3. Immunotherapy Targeted Therapy
    • 5.3.4. Other
  • 5.4. By Drug Class
    • 5.4.1. Immunosuppressant
    • 5.4.2. Monoclonal Antibodies
    • 5.4.3. Tyrosine Kinase
    • 5.4.4. Epidermal Growth Factors Receptors
    • 5.4.5. Topoisomerase Inhibitors
    • 5.4.6. Others
  • 5.5. By Route of Administration
    • 5.5.1. Oral
    • 5.5.2. Injectable
  • 5.6. By Distribution Channel
    • 5.6.1. Hospital
    • 5.6.2. Specialty Clinics
    • 5.6.3. Clinical Research Institutes
    • 5.6.4. Home Care Settings
    • 5.6.5. Ambulatory Surgical Centres
  • 5.7. By Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia-Pacific
    • 5.7.4. South America
    • 5.7.5. Middle East & Africa
  • 5.8. By Company Market Share (%), 2022

6. Global Lung Cancer Therapeutics Market Outlook, By Region, 2016-2030F

  • 6.1. North America*
    • 6.1.1. Market Size & Forecast
      • 6.1.1.1. By Value
      • 6.1.1.2. By Volume
    • 6.1.2. By Disease Type
      • 6.1.2.1. Non-small Cell Lung Cancer (NSCLC)
      • 6.1.2.2. Small Cell Lung Cancer (SCLC)
    • 6.1.3. By Treatment
      • 6.1.3.1. Chemotherapy
      • 6.1.3.2. Radiation Therapy
      • 6.1.3.3. Immunotherapy Targeted Therapy
      • 6.1.3.4. Other
    • 6.1.4. By Drug Class
      • 6.1.4.1. Immunosuppressant
      • 6.1.4.2. Monoclonal Antibodies
      • 6.1.4.3. Tyrosine Kinase
      • 6.1.4.4. Epidermal Growth Factors Receptors
      • 6.1.4.5. Topoisomerase Inhibitors
      • 6.1.4.6. Others
    • 6.1.5. By Route of Administration
      • 6.1.5.1. Oral
      • 6.1.5.2. Injectable
    • 6.1.6. By Distribution Channel
      • 6.1.6.1. Hospital
      • 6.1.6.2. Specialty Clinics
      • 6.1.6.3. Clinical Research Institutes
      • 6.1.6.4. Home Care Settings
      • 6.1.6.5. Ambulatory Surgical Centres
    • 6.1.7. United States*
      • 6.1.7.1. Market Size & Forecast
      • 6.1.7.1.1. By Value
      • 6.1.7.1.2. By Volume
      • 6.1.7.2. By Disease Type
      • 6.1.7.2.1. Non-small Cell Lung Cancer (NSCLC)
      • 6.1.7.2.2. Small Cell Lung Cancer (SCLC)
      • 6.1.7.3. By Treatment
      • 6.1.7.3.1. Chemotherapy
      • 6.1.7.3.2. Radiation Therapy
      • 6.1.7.3.3. Immunotherapy Targeted Therapy
      • 6.1.7.3.4. Others
      • 6.1.7.4. By Drug Class
      • 6.1.7.4.1.1. Immunosuppressant
      • 6.1.7.4.1.2. Monoclonal Antibodies
      • 6.1.7.4.1.3. Tyrosine Kinase
      • 6.1.7.4.1.4. Epidermal Growth Factors Receptors
      • 6.1.7.4.1.5. Topoisomerase Inhibitors
      • 6.1.7.4.1.6. Other
      • 6.1.7.5. By Route of Administration
      • 6.1.7.5.1.1. Oral
      • 6.1.7.5.1.2. Injectable
      • 6.1.7.6. By Distribution Channel
      • 6.1.7.6.1.1. Hospital
      • 6.1.7.6.1.2. Specialty Clinics
      • 6.1.7.6.1.3. Clinical Research Institutes
      • 6.1.7.6.1.4. Home Care Settings
      • 6.1.7.6.1.5. Ambulatory Surgical Centres
    • 6.1.8. Canada
    • 6.1.9. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2022

  • 7.1. By Disease Type
  • 7.2. By Treatment
  • 7.3. By Drug Class
  • 7.4. By Route of Administration
  • 7.5. By Distribution Channel
  • 7.6. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Novartis AG
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. AstraZeneca
  • 14.3. Boehringer Ingelheim
  • 14.4. Bristol-Myers Squibb Company
  • 14.5. Eli Lilly and Company
  • 14.6. Hoffmann-La Roche
  • 14.7. Merck & Co.
  • 14.8. Pfizer Inc.
  • 14.9. Teva Pharmaceutical Industries Ltd.
  • 14.10. Abbvie (Allergan)
  • 14.11. Johnson & Johnson (Janssen Pharmaceuticals)
  • 14.12. Amgen Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 2. Global Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 3. Global Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 4. Global Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 5. Global Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 6. Global Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 7. Global Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 8. Global Lung Cancer Therapeutics Market Share, By Region, In USD Billion, 2016-2030F
  • Figure 9. North America Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 10. North America Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 11. North America Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 12. North America Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 13. North America Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 14. North America Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 15. North America Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 16. North America Lung Cancer Therapeutics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 17. United States Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 18. United States Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 19. United States Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 20. United States Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 21. United States Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 22. United States Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 23. United States Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 24. Canada Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 25. Canada Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 26. Canada Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 27. Canada Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 28. Canada Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 29. Canada Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 30. Canada Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 31. Mexico Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 32. Mexico Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 33. Mexico Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 34. Mexico Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 35. Mexico Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 36. Mexico Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 37. Mexico Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 38. Europe Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 39. Europe Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 40. Europe Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 41. Europe Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 42. Europe Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 43. Europe Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 44. Europe Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 45. Europe Lung Cancer Therapeutics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 46. Germany Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 47. Germany Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 48. Germany Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 49. Germany Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 50. Germany Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 51. Germany Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 52. Germany Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 53. France Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 54. France Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 55. France Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 56. France Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 57. France Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 58. France Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 59. France Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 60. Italy Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 61. Italy Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 62. Italy Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 63. Italy Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 64. Italy Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 65. Italy Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 66. Italy Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 67. United Kingdom Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 68. United Kingdom Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 69. United Kingdom Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 70. United Kingdom Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 71. United Kingdom Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 72. United Kingdom Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 73. United Kingdom Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 74. Russia Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 75. Russia Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 76. Russia Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 77. Russia Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 78. Russia Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 79. Russia Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 80. Russia Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 81. Netherlands Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 82. Netherlands Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 83. Netherlands Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 84. Netherlands Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 85. Netherlands Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 86. Netherlands Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 87. Netherlands Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 88. Spain Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 89. Spain Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 90. Spain Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 91. Spain Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 92. Spain Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 93. Spain Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 94. Spain Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 95. Turkey Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 96. Turkey Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 97. Turkey Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 98. Turkey Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 99. Turkey Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 100. Turkey Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 101. Turkey Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 102. Poland Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 103. Poland Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 104. Poland Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 105. Poland Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 106. Poland Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 107. Poland Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 108. Poland Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 109. South America Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 110. South America Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 111. South America Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 112. South America Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 113. South America Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 114. South America Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 115. South America Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 116. South America Lung Cancer Therapeutics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 117. Brazil Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 118. Brazil Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 119. Brazil Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 120. Brazil Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 121. Brazil Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 122. Brazil Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 123. Brazil Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 124. Argentina Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 125. Argentina Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 126. Argentina Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 127. Argentina Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 128. Argentina Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 129. Argentina Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 130. Argentina Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 131. Asia-Pacific Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 132. Asia-Pacific Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 133. Asia-Pacific Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 134. Asia-Pacific Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 135. Asia-Pacific Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 136. Asia-Pacific Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 137. Asia- Pacific Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 138. Asia-Pacific Lung Cancer Therapeutics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 139. India Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 140. India Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 141. India Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 142. India Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 143. India Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 144. India Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 145. India Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 146. China Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 147. China Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 148. China Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 149. China Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 150. China Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 151. China Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 152. China Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 153. Japan Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 154. Japan Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 155. Japan Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 156. Japan Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 157. Japan Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 158. Japan Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 159. Japan Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 160. Australia Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 161. Australia Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 162. Australia Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 163. Australia Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 164. Australia Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 165. Australia Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 166. Australia Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 167. Vietnam Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 168. Vietnam Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 169. Vietnam Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 170. Vietnam Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 171. Vietnam Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 172. Vietnam Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 173. Vietnam Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 174. South Korea Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 175. South Korea Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 176. South Korea Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 177. South Korea Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 178. South Korea Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 179. South Korea Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 180. South Korea Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 181. Indonesia Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 182. Indonesia Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 183. Indonesia Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 184. Indonesia Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 185. Indonesia Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 186. Indonesia Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 187. Indonesia Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 188. Philippines Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 189. Philippines Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 190. Philippines Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 191. Philippines Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 192. Philippines Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 193. Philippines Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 194. Philippines Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 195. Middle East & Africa Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 196. Middle East & Africa Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 197. Middle East & Africa Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 198. Middle East & Africa Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 199. Middle East & Africa Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 200. Middle East & Africa Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 201. Middle East & Africa Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 202. Middle East & Africa Lung Cancer Therapeutics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 203. Saudi Arabia Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 204. Saudi Arabia Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 205. Saudi Arabia Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 206. Saudi Arabia Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 207. Saudi Arabia Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 208. Saudi Arabia Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 209. Saudi Arabia Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 210. UAE Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 211. UAE Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 212. UAE Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 213. UAE Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 214. UAE Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 215. UAE Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 216. UAE Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 217. South Africa Lung Cancer Therapeutics Market, By Value, In USD Billion, 2016-2030F
  • Figure 218. South Africa Lung Cancer Therapeutics Market, By Volume, In Million Units, 2016-2030F
  • Figure 219. South Africa Lung Cancer Therapeutics Market Share, By Disease Type, In USD Billion, 2016-2030F
  • Figure 220. South Africa Lung Cancer Therapeutics Market Share, By Treatment, In USD Billion, 2016-2030F
  • Figure 221. South Africa Lung Cancer Therapeutics Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 222. South Africa Lung Cancer Therapeutics Market Share, By Route of Administration, In USD Billion, 2016-2030F
  • Figure 223. South Africa Lung Cancer Therapeutics Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 224. By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 225. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 226. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 227. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 228. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022